CAPTRUST Financial Advisors
EWTX icon

CAPTRUST Financial Advisors’s Edgewise Therapeutics EWTX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-263
Closed -$2K – 2692
2022
Q2 		$2K Buy
+263
New +$1.99K ﹤0.01% 4449

Other funds holding EWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAPTRUST Financial Advisors's EWTX Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Edgewise Therapeutics (EWTX) in Q3 2022, closing a stake of 263 shares — an estimated $2K sold.

CAPTRUST Financial Advisors first reported a position in EWTX in Q2 2022 and held it in 1 quarter. The position peaked at $2K in Q2 2022. 94 funds tracked by Wall St. Rank hold EWTX as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Edgewise Therapeutics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 263 Edgewise Therapeutics shares in Q3 2022, an estimated $2K.
  • CAPTRUST Financial Advisors first reported a position in Edgewise Therapeutics in Q2 2022 and held it in 1 quarter.
  • CAPTRUST Financial Advisors's Edgewise Therapeutics position peaked at $2K in Q2 2022.
  • 94 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.